TCGA-DQ-7588-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.097488584
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.660
- MYC_TARGETS_V2+0.660
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.550
- MTORC1_SIGNALING+0.460
- OXIDATIVE_PHOSPHORYLATION+0.450
- DNA_REPAIR+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.390
- GLYCOLYSIS+0.380
- MITOTIC_SPINDLE+0.320
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.360
- APICAL_SURFACE-0.330
- KRAS_SIGNALING_UP-0.310
- ANGIOGENESIS-0.270
- COMPLEMENT-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1063 | — | — | 0.932 |
| 2 | SRR26320071 | — | — | 0.928 |
| 3 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.917 |
| 4 | SRR8613799 | — | E | 0.916 |
| 5 | SRR4296106 | — | cohortSQ1 | 0.915 |
| 6 | MNG534 | — | — | 0.908 |
| 7 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.905 |
| 8 | SRR25043616 | — | — | 0.905 |
| 9 | MDT-AP-2956 | Med | Medulloblastoma | 0.903 |
| 10 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.660 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.660 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |